The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils

International Journal of Cardiology

Volumn 75, Issue 1, 2000, Pages 85-90

  Deskur Smielecka, Ewa ^a   Wykretowicz, Andrzej ^a   Banaszak, Agnieszka ^a   Szczepanik, Adam ^a   Furmaniuk, Jaromir ^a   Wysocki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Hypercholesterolemia; Neutrophil; Simvastatin

Indexed keywords

SIMVASTATIN;

ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NEUTROPHIL; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CHEMOTAXIS, LEUKOCYTE; COMPARATIVE STUDY; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGE; NEUTROPHILS; SIMVASTATIN; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS;

EID: 0033779741     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00302-8     Document Type: Article

References (29)

1. Respiratory burst is decreased by human hyperlipemic serum in rat peritoneal macrophages
2. Effects of human low-density lipoproteins on superoxide production by formyl-methionyl-leucyl-phenylalanine activated polymorphonuclear leukocytes
3. Effects of low-density lipoproteins on polymorphonuclear leukocyte functions in vitro
4. Suppression of lymphocyte activation by plasma lipoproteins: modulation by cell number and type
5. Oxidative burst and lysosomal enzyme release by polymorphonuclear cells in type IIa, type IIb and type IV primary hyperlipoproteinaemia
6. Cholesterol feeding enhances vasoconstrictor effects of products from rabbit polymorphonuclear leukocytes
7. Increased leukocyte aggregation in patients with hypercholesterolemia
8. In vitro alteration of macrophage phenotype and function by serum lipids
9. Neutrophil dysfunction in the rabbit model of spur cell anemia
10. Alterations of host defences paralleling cholesterol-induced atherogenesis. II. Immunologic studies of rabbits
11. Human monocyte characteristics are altered in hypercholesterolaemia
12. Functional characterisation of mononuclear cells of normal and hypercholesterolemic rabbits
13. Alterations of host defences paralleling cholesterol-induced atherogenesis. I: Interactions of prolonged experimental hypercholesterolemia and infections
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
15. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
16. Direct effects of statins on the vascular wall
17. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month
18. Hyperlipidaemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction
19. for the Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
20. Role of the mevalonate pathway of isoprenoid synthesis in Il-8 generation by activated monocytic cells
21. Isolation of mononuclear cells and granulocytes from human blood
22. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
23. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin
24. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
25. Effects of fluvastatin on leukocyteendothelial cell adhesion in hypercholesterolemic rats
26. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
27. Simvastatin
28. Late lumen loss after angioplasty is associated with the activation status of circulating phagocytes before treatment